{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:43:58Z","timestamp":1787161438362,"version":"build-2736575974"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2006,12,20]],"date-time":"2006-12-20T00:00:00Z","timestamp":1166572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,1,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Both CC- and CXC-chemokines are known to be potent leucocyte activators and chemoattractants and play important roles in inflammatory responses. However, chemokine response to bacillus Calmette\u2013Gu\u00e9rin (BCG) infection remains incompletely defined. In this study, we investigated human CC- [macrophage-derived chemokine (MDC), monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1\u03b1 and eosinophil chemoattractant activity (eotaxin)] and CXC-interferon-inducible protein (IP)-10 chemokine production in response to BCG stimulation. BCG efficiently induced all chemokines tested in the urine of four bladder cancer patients undergoing intravesical BCG immunotherapy. The peak urinary chemokine responses occurred generally between the fourth and sixth weekly treatment, except eotaxin, which was less predictable. To evaluate the effect of BCG on induction of chemokines in vitro, urothelial cell lines and peripheral blood mononuclear cells (PBMCs) were used. Although BCG induced no or marginal chemokines from urothelial SV-HUC-1, RT4 and T24 cells, BCG-derived cytokines [interleukin (IL)-1\u03b2, interferon (IFN)-\u03b3 and tumour necrosis factor (TNF)-\u03b1] induced all chemokines tested except eotaxin from these cell lines. BCG also efficiently induced all chemokines tested except eotaxin from PBMCs of both BCG-naive and BCG-vaccinated subjects. MCP-1 and MIP-1\u03b1 emerged at 4\u20135\u2003h post-BCG exposure (early chemokines); IP-10 elevated at day 1 and peaked at day 2 (intermediate chemokine); and MDC elevated at day 1 and peaked at day 7 (late chemokine). This kinetic pattern was paralleled with that of BCG-induced cytokines [early: TNF-\u03b1; intermediate: IL-6 and IL-10; and late: IFN-\u03b3 and granulocyte\u2013macrophage colony-stimulating factor (GM-CSF)]. Taken together, these results indicate that BCG directly or indirectly induces human CC- and CXC-chemokine production, which may represent one of the mechanisms by which BCG exerts its anti-tumour activity.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2006.03288.x","type":"journal-article","created":{"date-parts":[[2010,8,12]],"date-time":"2010-08-12T10:08:27Z","timestamp":1281607707000},"page":"370-378","source":"Crossref","is-referenced-by-count":46,"title":["<i>Mycobacterium bovis<\/i>\n                    bacillus Calmette\u2013Gu\u00e9rin (BCG) induces human CC- and CXC-chemokines\n                    <i>in vitro<\/i>\n                    and\n                    <i>in vivo<\/i>"],"prefix":"10.1093","volume":"147","author":[{"given":"Y","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,12,20]]},"reference":[{"key":"2022010415135136500_b1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.immunol.18.1.217","article-title":"The biology of chemokines and their receptors","volume":"18","author":"Rossi","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"2022010415135136500_b2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1074-7613(00)80165-X","article-title":"Chemokines: a new classification system and their role in immunity","volume":"12","author":"Zlotnik","year":"2000","journal-title":"Immunity"},{"key":"2022010415135136500_b3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/84298","article-title":"Chemokines: immunology's high impact factors","volume":"2","author":"Mackay","year":"2001","journal-title":"Nat Immunol"},{"key":"2022010415135136500_b4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1359-6101(01)00033-8","article-title":"Chemokines in cancer","volume":"13","author":"Vicari","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"2022010415135136500_b5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/84209","article-title":"Chemokines and disease","volume":"2","author":"Gerard","year":"2001","journal-title":"Nat Immunol"},{"key":"2022010415135136500_b6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"Bacillus Calmette\u2013Gu\u00e9rin immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J Urol"},{"key":"2022010415135136500_b7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1055-3207(18)30447-2","article-title":"Bacillus Calmette\u2013Gu\u00e9rin immunotherapy for superficial bladder cancer. New prospects for an old warhorse","volume":"4","author":"O'Donnell","year":"1995","journal-title":"Surg Oncol Clin N Am"},{"key":"2022010415135136500_b8","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0140-6736(98)07422-4","article-title":"BCG immunotherapy of bladder cancer: 20 years on","volume":"353","author":"Alexandroff","year":"1999","journal-title":"Lancet"},{"key":"2022010415135136500_b9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0090-4295(91)80127-S","article-title":"Bacillus Calmette\u2013Guerin (BCG): mechanism of action in superficial bladder cancer","volume":"37","author":"Ratliff","year":"1991","journal-title":"Urology"},{"key":"2022010415135136500_b10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-5347(17)39365-5","article-title":"Effects of local bacillus Calmette\u2013Gu\u00e9rin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall","volume":"144","author":"Bohle","year":"1990","journal-title":"J Urol"},{"key":"2022010415135136500_b11","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","article-title":"Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall","volume":"147","author":"Prescott","year":"1992","journal-title":"J Urol"},{"key":"2022010415135136500_b12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF00262987","article-title":"Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical bacillus Calmette\u2013Gu\u00e9rin","volume":"17","author":"Peuchmaur","year":"1989","journal-title":"Urol Res"},{"key":"2022010415135136500_b13","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1046\/j.1464-410X.2001.02394.x","article-title":"Evaluation of cellular tumor rejection mechanisms in the peritumoral bladder wall after bacillus Calmette\u2013Gu\u00e9rin treatment","volume":"88","author":"Saint","year":"2001","journal-title":"BJU Int"},{"key":"2022010415135136500_b14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF01741603","article-title":"Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette\u2013Gu\u00e9rin","volume":"33","author":"De Boer","year":"1991","journal-title":"Cancer Immunol Immunother"},{"key":"2022010415135136500_b15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00294021","article-title":"Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis","volume":"19","author":"De Boer","year":"1991","journal-title":"Urol Res"},{"key":"2022010415135136500_b16","first-page":"671","article-title":"Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette\u2013Gu\u00e9rin","volume":"5","author":"De Boer","year":"1991","journal-title":"In Vivo"},{"key":"2022010415135136500_b17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-5347(17)39366-7","article-title":"Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette\u2013Gu\u00e9rin immunotherapy","volume":"144","author":"Bohle","year":"1990","journal-title":"J Urol"},{"key":"2022010415135136500_b18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-5347(01)66424-3","article-title":"Urinary cytokines during intravesical bacillus Calmette\u2013Gu\u00e9rin therapy for superficial bladder cancer: processing, stability and prognostic value","volume":"155","author":"De Reijke","year":"1996","journal-title":"J Urol"},{"key":"2022010415135136500_b19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","article-title":"Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette\u2013Gu\u00e9rin treatment for superficial bladder cancer","volume":"167","author":"Saint","year":"2002","journal-title":"J Urol"},{"key":"2022010415135136500_b20","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette\u2013Gu\u00e9rin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J Urol"},{"key":"2022010415135136500_b21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0090-4295(98)00188-5","article-title":"Intravesical bacille Calmette\u2013Guerin induces the antiangiogenic chemokine interferon-inducible protein 10","volume":"52","author":"Poppas","year":"1998","journal-title":"Urology"},{"key":"2022010415135136500_b22","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/S0022-5347(05)67620-3","article-title":"BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation","volume":"163","author":"Pavlovich","year":"2000","journal-title":"J Urol"},{"key":"2022010415135136500_b23","first-page":"3041","article-title":"Serial urinary IL-2, IL-6, IL-8, TNF-alpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG","volume":"21","author":"Sanchez-Carbayo","year":"2001","journal-title":"Anticancer Res"},{"key":"2022010415135136500_b24","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/S0022-5347(05)64361-3","article-title":"Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette\u2013Guerin (modified Danish 1331 strain) for superficial bladder cancer","volume":"168","author":"Kumar","year":"2002","journal-title":"J Urol"},{"key":"2022010415135136500_b25","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/S0022-5347(05)65522-X","article-title":"T helper 1\/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette\u2013Guerin for superficial bladder cancer","volume":"166","author":"Saint","year":"2001","journal-title":"J Urol"},{"key":"2022010415135136500_b26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1365-2249.2003.02071.x","article-title":"Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette\u2013Guerin (BCG) mediated antitumour activity","volume":"131","author":"Nadler","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"2022010415135136500_b27","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1128\/iai.62.6.2508-2514.1994","article-title":"Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes","volume":"62","author":"O'Donnell","year":"1994","journal-title":"Infect Immun"},{"key":"2022010415135136500_b28","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","article-title":"IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette\u2013Guerin immunotherapy","volume":"162","author":"Luo","year":"1999","journal-title":"J Immunol"},{"key":"2022010415135136500_b29","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.4049\/jimmunol.163.8.4246","article-title":"Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette\u2013Guerin","volume":"163","author":"O'Donnell","year":"1999","journal-title":"J Immunol"},{"key":"2022010415135136500_b30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00296835","article-title":"Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette\u2013Guerin (BCG)","volume":"21","author":"De Reijke","year":"1993","journal-title":"Urol Res"},{"key":"2022010415135136500_b31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1464-410X.1997.00211.x","article-title":"Effects of isoniazid on the proliferation and cytokine production of bladder cancer cells in vitro induced by bacille Calmette\u2013Guerin","volume":"80","author":"Bevers","year":"1997","journal-title":"Br J Urol"},{"key":"2022010415135136500_b32","first-page":"181","article-title":"BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines","volume":"9","author":"Bevers","year":"1998","journal-title":"Eur Cytokine Netw"},{"key":"2022010415135136500_b33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0022-5347(01)67113-1","article-title":"Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy","volume":"154","author":"Esuvaranathan","year":"1995","journal-title":"J Urol"},{"key":"2022010415135136500_b34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00262-001-0254-2","article-title":"Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette\u2013Guerin immunotherapy","volume":"51","author":"Reale","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"2022010415135136500_b35","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.urology.2005.07.049","article-title":"Human detrusor smooth muscle cells release interleukin-6, interleukin-8, and RANTES in response to proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha","volume":"67","author":"Bouchelouche","year":"2006","journal-title":"Urology"},{"key":"2022010415135136500_b36","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0022-5347(05)00167-9","article-title":"Interleukin-4 and 13 induce the expression and release of monocyte chemoattractant protein 1, interleukin-6 and stem cell factor from human detrusor smooth muscle cells: synergy with interleukin-1beta and tumor necrosis factor-alpha","volume":"175","author":"Bouchelouche","year":"2006","journal-title":"J Urol"},{"key":"2022010415135136500_b37","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/01.ju.0000090192.36436.d5","article-title":"Monocyte chemoattractant protein-1 production by human detrusor smooth muscle cells","volume":"171","author":"Bouchelouche","year":"2004","journal-title":"J Urol"},{"key":"2022010415135136500_b38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/(SICI)1097-0215(19970529)71:5<851::AID-IJC25>3.0.CO;2-9","article-title":"Effects of bacillus Calmette\u2013Guerin and interferon-alpha-2B on human bladder cancer in vitro","volume":"71","author":"Zhang","year":"1997","journal-title":"Int J Cancer"},{"key":"2022010415135136500_b39","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0022-5347(01)61832-9","article-title":"Effects of bacillus Calmette\u2013Guerin and interferon alpha-2B on cytokine production in human bladder cancer cell lines","volume":"161","author":"Zhang","year":"1999","journal-title":"J Urol"},{"key":"2022010415135136500_b40","volume-title":"The cytokine network and immune functions","author":"Th\u00e8ze","year":"1999"},{"key":"2022010415135136500_b41","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0167-5699(99)01469-3","article-title":"The chemokine system: redundancy for robust outputs","volume":"20","author":"Mantovani","year":"1999","journal-title":"Immunol Today"},{"key":"2022010415135136500_b42","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood.V95.10.3032","article-title":"Chemokine receptors and their role in inflammation and infectious diseases","volume":"95","author":"Murdoch","year":"2000","journal-title":"Blood"},{"key":"2022010415135136500_b43","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1084\/jem.185.9.1595","article-title":"Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells","volume":"185","author":"Godiska","year":"1997","journal-title":"J Exp Med"},{"key":"2022010415135136500_b44","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1006\/cyto.1999.0487","article-title":"Dermal fibroblasts represent a potent major source of human eotaxin: in vitro production and cytokine-mediated regulation","volume":"11","author":"Miyamasu","year":"1999","journal-title":"Cytokine"},{"key":"2022010415135136500_b45","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000093206","article-title":"Endothelial and epithelial expression of eotaxin-2 (CCL24) in nasal polyps","volume":"140","author":"Schaefer","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"key":"2022010415135136500_b46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.bjc.6602026","article-title":"Role of urothelial cells in BCG immunotherapy for superficial bladder cancer","volume":"91","author":"Bevers","year":"2004","journal-title":"Br J Cancer"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2006.03288.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/147\/2\/370\/42057386\/j.1365-2249.2006.03288.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/147\/2\/370\/42057386\/j.1365-2249.2006.03288.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:09:39Z","timestamp":1740362979000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/147\/2\/370\/6457237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,20]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2006,12,20]]},"published-print":{"date-parts":[[2007,1,5]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2006.03288.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,2]]},"published":{"date-parts":[[2006,12,20]]}}}